Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474188 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 2 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00474188 is a Phase 2 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 26 participants.
The verdict
NCT00474188, a Phase 2 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
Interventions
- DRUG dexamethasone
- DRUG CC-5013 (lenalidomide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00474188
The ClinicalTrials.gov registry entry for NCT00474188 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00474188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00474188 about?
NCT00474188 is a clinical study titled "A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma". To evaluate the safety and efficacy of lenalidomide (Revlimid ®) in combination with dexamethasone in subjects with relapsed or refractory diffuse large B-cell lymphoma.
What is the current status of trial NCT00474188?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2007-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00474188?
The interventions under investigation include: dexamethasone (DRUG), CC-5013 (lenalidomide) (DRUG).
Who is sponsoring clinical trial NCT00474188?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.